The company’s recent performance reflects a pivot toward operational discipline, marked by a 17 percent global workforce reduction expected to yield $10 million in annualized savings. While ZYNLONTA continues to generate steady revenue as a monotherapy for late-stage diffuse large B-cell lymphoma, the FDA has raised significant concerns regarding the benefit-risk profile observed in the LOTIS-5 study, specifically citing an imbalance in Grade 5 events.

In response, management is shifting focus toward the company's combination therapy pipeline. Enrollment for the LOTIS-7 trial—which pairs ZYNLONTA with the bispecific antibody glofitamab—is now complete. The firm views these results as potentially practice-changing and is currently assessing a Phase 3 trial for the combination. CEO Ameet Mallik emphasized that despite the regulatory hurdles, the company remains committed to securing a foundational position in earlier lines of DLBCL treatment. ADC Therapeutics ended the quarter with $219.1 million in cash and cash equivalents, providing a runway into 2028 as it works to address FDA feedback and advance its clinical portfolio.